KPMG Survey Reveals CEOs See Financial Drivers for M&A
KPMG, a professional services firm providing business solutions and audit, tax, and advisory services, released its CEO Outlook survey results. The survey found that low interest rates and high stock valuations are fueling U.S. life sciences CEOs’ growing appetite for mergers and acquisitions.
Some key takeaways from the survey include:
- 43% of U.S. life sciences CEOs say they have a “high appetite” for M&A, an increase from 33% a year ago.
- 58% of U.S. CEOs said using cheap financing, such as low interest rates before they rise, are a primary driver of deals during the next three years.
- 48% of those in the U.S. pointed to favorable stock valuations as a motivator for deals.
- 44% of life sciences CEOs globally found that business-model transformation was the leading driver of M&A, followed by improving market share and also capitalizing on low interest rates (both 39%).
- Cost cutting was seen as a motivator equally among global and U.S. CEOs (39%).
To view the full survey, visit here.
Sanofi Bolsters Immunology Pipeline with Acquisition of Dren Bio’s DR-0201 for Up to $1.9 Billion
March 20th 2025DR-0201, a CD20-directed bispecific antibody, has demonstrated robust B-cell depletion in early clinical studies, showing promise in treating refractory B-cell-mediated autoimmune diseases.
The Misinformation Maze: Navigating Public Health in the Digital Age
March 11th 2025Jennifer Butler, chief commercial officer of Pleio, discusses misinformation's threat to public health, where patients are turning for trustworthy health information, the industry's pivot to peer-to-patient strategies to educate patients, and more.
Navigating Distrust: Pharma in the Age of Social Media
February 18th 2025Ian Baer, Founder and CEO of Sooth, discusses how the growing distrust in social media will impact industry marketing strategies and the relationships between pharmaceutical companies and the patients they aim to serve. He also explains dark social, how to combat misinformation, closing the trust gap, and more.
Phase III Trials Show Povorcitinib Significantly Improves Hidradenitis Suppurativa Outcomes
March 19th 2025In the Phase III STOP-HS1 and STOP-HS2 trials, results show that patients treated with povorcitinib for hidradenitis suppurativa experienced a ≥50% reduction in the total abscess and inflammatory nodule count.
